IP Library Granted Patent US 11,541,002
Granted Patent B2
US 11,541,002 · App. 16/561,573 · Granted Jan 3, 2023

Oral film compositions and dosage forms having precise active dissolution profiles

Inventors: Alexander Mark Schobel (Vero Beach, FL); Stephen Wargacki (Pittstown, NJ); Vincent J. Buono (Basking Ridge, NJ); Susan Shumard (Green Brook, NJ); Christopher James Santee (Portage, IN)
Assignee: Aquestive Therapeutics, Inc.
A61K9/006A61K31/5513A61P25/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,541,002
App. No.
16/561,573
Granted
Jan 3, 2023
Kind
B2
Abstract

An oral film in an individual unit dose for delivery of one or more actives is disclosed herein, the film having a precisely calculated and controlled active dissolution profile. A wide variety of actives may be used, including, for example, clobazam, diazepam, or riluzole. Also disclosed are methods of treating a variety of diseases and conditions, for example, epilepsy and seizures, by administering the oral film disclosed herein.

Claims (28)

1. A self-supporting oral film for delivery of a desired amount of an active in an individual unit dose, said film comprising:

a) a water-soluble polymer matrix, a water swellable polymer matrix, or a water-soluble and water swellable polymer matrix;

b) the active being clobazam and having an average particle size D90 of less than about 160 microns; and

c) an additive selected from the group consisting of a sweetener, a flavor, a flavor enhancer, a filler, a plasticizer, a dye, a pigment, a permeation enhancer, a buffer, a preservative, silicon dioxide, an anti-tacking agent, and any combination thereof;

wherein, upon placing the film in a medium, about 40% or more of the active is dissolved in the medium after about 5 minutes.

2. The film of claim 1 , wherein the active has an average particle size D90 of less than about 120 microns.

3. The film of claim 1 , wherein the active has an average particle size D50 of less than about 30 microns.

4. The film of claim 2 , wherein the active has an average particle size D10 of less than about 10 microns.

5. The film of claim 1 , wherein, upon placing the film in the medium, more than about 55% of the active is dissolved after about 5 minutes.

6. The film of claim 1 , wherein, upon placing the film in the medium, more than about 5% of the active is dissolved after about 1.5 minutes.

7. The film of claim 1 , wherein the individual unit dose contains about 2 mg to about 20 mg of clobazam.

8. The film of claim 7 , wherein the individual unit dose contains about 5 mg of clobazam.

9. The film of claim 8 , wherein, upon placing the film in the medium, more than about 30% of the active is dissolved after about 1 minute.

10. The film of claim 8 , wherein, upon placing the film in the medium, more than about 70% of the active is dissolved after about 2 minutes.

11. The film of claim 8 , wherein, upon placing the film in the medium, more than about 90% of the active is dissolved after about 2.5 minutes.

12. The film of claim 7 , wherein the individual unit dose contains about 10 mg of clobazam.

13. The film of claim 12 , wherein, upon placing the film in the medium, more than about 50% of the active is dissolved after about 1.5 minutes.

14. The film of claim 12 , wherein, upon placing the film in the medium, more than about 70% of the active is dissolved after about 2.5 minutes.

15. The film of claim 7 , wherein the individual unit dose contains about 20 mg of clobazam.

16. The film of claim 15 , wherein, upon placing the film in the medium, more than about 2% of the active is dissolved after about 1.5 minutes.

17. The film of claim 15 , wherein, upon placing the film in the medium, more than about 40% of the active is dissolved after about 3.5 minutes.

18. A method of treating epilepsy and/or seizures in a human comprising administering to said human the oral film individual unit dose of claim 1 .

19. The film of claim 1 , wherein, upon placing the film in the medium about 20% or more of the active is dissolved in the medium after about 3 minutes.

20. The film of claim 1 , wherein the water-soluble polymer matrix, the water swellable polymer matrix, or the water-soluble and water swellable polymer matrix comprise a polymer selected from polyethylene oxide (PEO), pullulan, hydroxypropylmethyl cellulose (HPMC), hydroxyethyl cellulose (HPC), hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyethylene glycol, xanthan gum, tragancanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methyl-methacrylate copolymer, carboxyvinyl copolymers, starch, gelatin, and combinations thereof.

21. The film of claim 20 , wherein the polymer is polyethylene oxide (PEO).

22. The film of claim 21 , wherein the polyethylene oxide has a molecular weight of at least about 100,000.

23. The film of claim 21 , wherein the polyethylene oxide has a molecular weight from about 100,000 to 300,000.

24. The film of claim 1 , wherein the active has an average particle size D90 of about 8 microns to no more than about 160 microns.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 075646/0258 →
SECURITY INTEREST Recorded May 12, 2026
From: AQUESTIVE THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075561/0782 →
SECURITY INTEREST Recorded Nov 2, 2023
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065446/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2021
From: SCHOBEL, ALEXANDER MARK; WARGACKI, STEPHEN; BUONO, VINCENT J.; SHUMARD, SUSAN; SANTEE, CHRISTOPHER JAMES
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 055492/0078 →
Continuity (3)
Provisional Application 62732720 · Sep 18, 2018
Provisional Application 62728187 · Sep 7, 2018
Related Publication 20200101009A1 · Apr 2, 2020